ArriVent BioPharma, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-20$31.39 RISE2026-05-19$26.15 PEAK2026-05-29$30.27 39d | -16.7% 29d | Missed | Missed | — | — | +15.8% 10d | Missed |
DROP2026-03-04$26.56 RISE2026-03-30$21.01 PEAK2026-04-20$31.39 47d | -20.9% 26d | Missed | Missed | — | — | +49.4% 21d | Missed |
DROP2025-12-08$24.98 RISE2026-01-06$18.93 PEAK2026-03-04$26.56 86d | -24.2% 29d | Missed | Missed | — | — | +40.3% 57d | Missed |
DROP2025-06-27$22.91 RISE2025-11-03$17.60 PEAK2026-01-22$25.20 209d | -23.2% 129d | Missed | Missed | — | — | +43.2% 80d | Missed |
DROP2025-06-16$25.42 RISE2025-09-25$17.17 PEAK2025-12-08$24.98 175d | -32.5% 101d | Missed | Missed | — | — | +45.5% 74d | Missed |
DROP2025-06-16$25.42 RISE2025-08-12$16.95 PEAK2025-10-09$21.13 115d | -33.3% 57d | Missed | Missed | — | — | +24.7% 58d | Missed |
DROP2024-11-29$29.96 RISE2025-04-08$16.30 PEAK2025-06-16$25.42 199d | -45.6% 130d | Missed | Missed | — | — | +56.0% 69d | Missed |
DROP2024-11-07$35.63 RISE2025-01-17$24.41 PEAK2025-02-05$29.25 90d | -31.5% 71d | Missed | Missed | — | — | +19.8% 19d | Missed |
DROP2024-09-06$28.01 RISE2024-09-23$22.64 PEAK2024-11-07$35.63 62d | -19.2% 17d | Missed | Missed | — | — | +57.4% 45d | Missed |
DROP2024-03-04$22.75 RISE2024-06-20$16.60 PEAK2024-09-06$28.01 186d | -27.0% 108d | Missed | Missed | — | — | +68.7% 78d | Missed |
DROP2024-03-04$22.75 RISE2024-04-24$15.30 PEAK2024-05-16$20.15 73d | -32.7% 51d | Missed | Missed | — | — | +31.7% 22d | Missed |
No scored news yet for a sentiment trend.
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $43 to $45.
ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term risk. Read why AVBP stock is a strong buy.
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $43.
A Late-Stage Company With a Global Oncology Portfolio May 2026 Corporate Presentation Accelerating a differentiated...
$250,000,000Common StockWe have entered into an Open Market Sale AgreementSM (the sales agreement) with Jefferies LLC (Jefferies), as our sales agent, relating to the shares of our common stock offered by this prospectus
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.86) by 11.63 percent. This is a 49.47 percent increase over losses of $(1.90) per share
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...
ArriVent BioPharma (AVBP) stock is in focus after the FDA cleared its investigational new drug application for ARR-002, a dual-target antibody drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharma. Despite a 2.6% 1-day share price return decline and a 7.2% 7-day pullback, ArriVent BioPharma’s 30-day and 90-day share price returns of 14.53% and 31.98%, alongside a 38.70% year to date share price return and 46.08% 1-year total shareholder return,...
Arrivent BioPharma Inc: Arrivent announces IND clearance for novel tetravalent MUC16/NAPI2B targeting ADC ARR-002 with initial focus in ovarian and endometrial cancers Arrivent BioPharma Inc -...
ArriVent BioPharma (AVBP) is advancing firmonertinib for EGFR mutant NSCLC, targeting underserved Exon 20 and PACC mutations.
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $33 to $45.
US stock futures rise, Vicor Corp shares dip 2.2% in pre-market trading after beating earnings and sales estimates. Other stocks also decline.
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Astrazeneca (AZN) and ArriVent BioPharma, Inc. (AVBP) have performed compared to their sector so far this year.
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Event driven snapshot of ArriVent BioPharma ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted closer scrutiny of how the stock’s latest price action lines up with its fundamentals. See our latest analysis for ArriVent BioPharma. At a share price of $24.89, ArriVent BioPharma has a 7 day share price return of 16.15% and a 90 day share price return of 19.66%, while the 1 year total...
Event driven snapshot of ArriVent BioPharma ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted closer scrutiny of how the stock’s latest price action lines up with its fundamentals. See our latest analysis for ArriVent BioPharma. At a share price of $24.89, ArriVent BioPharma has a 7 day share price return of 16.15% and a 90 day share price return of 19.66%, while the 1 year total...
Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AVBP | +0.93% | +30.59% | +50.45% | +42.45% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.04% | +36.30% | +53.89% | +29.76% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 3.02M | $69.58M | 0.00% | Trimmed-18.6% | 2026-03-31 |
| StateStreet | passive | 1.42M | $32.79M | 0.00% | Added+30.2% | 2026-03-31 |
| Citadel | multi-strat | 748.2K | $17.26M | 0.02% | Added+245.3% | 2026-03-31 |
| DEShaw | quant | 368.8K | $8.51M | 0.01% | Added+58.1% | 2026-03-31 |
| Wellington | fundamental | 78.2K | $1.80M | 0.00% | Trimmed-4.9% | 2026-03-31 |
| TwoSigma | quant | 48.7K | $1.12M | 0.00% | Trimmed-37.2% | 2026-03-31 |
| TRowePrice | fundamental | 22.6K | $522 | 0.00% | Added+40.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-14upcoming | -0.99 | — | — |
| 2026-05-11 | -0.89 | -0.96 | -7.40% |
| 2026-03-05 | -0.85 | -0.78 | +7.69% |
| 2025-11-10 | -0.78 | -0.83 | -6.02% |
| 2025-08-11 | -0.71 | -0.90 | -26.51% |
| 2025-05-12 | -0.69 | -1.90 | -175.36% |
| 2025-03-03 | -0.78 | -0.61 | +21.93% |
| 2024-11-14 | -1.07 | -0.61 | +42.83% |
| 2024-08-14 | -0.59 | -0.65 | -10.47% |
| 2024-05-08 | -1.30 | -0.70 | +46.00% |
| 2024-03-28 | -0.65 | -30.76 | -4632.31% |